|
|
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | I’d like to believe everyone reading Advancing RNA already knows that mRNA is the greatest. So, this article isn’t going to outline why the U.S. government’s current efforts to disparage mRNA are harmful. Rather, I’d like to focus on how these policies are impacting our industry in both positive and negative ways — starting with a few takeaways I gleaned from a discussion at RNA Leaders. | |
|
|
|
By Sabyasachi Ghosh, Future Market Insights | Contract manufacturing continues to emerge as the widely adopted model for bringing cell therapies, gene therapies, RNA therapeutics, and oligonucleotides to patients worldwide. | |
|
|
|
While EVPs (engineered viral-like particles) and extracellular vesicles (EVs) are still emerging technologies, panelists explain how developers can navigate regulatory expectations by adapting lessons learned from established viral vector products. Additionally, Aegle’s Gloria Matthews explains the benefits of working with EVs in comparison to LNPs. |
|
|
|
| Regulatory Frameworks For mRNA Therapeutics | White Paper | MilliporeSigma | The RNA therapeutics and vaccines market has grown rapidly, driven by siRNA and mRNA technologies. Explore how these advancements are now being applied to cancer vaccines and innovative therapeutics. |
|
|
|
| Choosing A CDMO: Three Considerations For New Drug Developers | Article | Curia | The greatest challenge in drug development can be finding a team capable of carrying a molecule through the complexities that lie between the research lab and the patient’s bedside. Discover three considerations that build a foundation for partnership. |
|
|
|
|
|
| High-Throughput Lipid Separation For LNP Formulations | Application Note | KNAUER | Lipid nanoparticles (LNPs) carry immense potential as delivery systems. Learn about the development of isocratic and gradient methods for high-throughput separation of lipids used in LNP formulations. |
|
|
|
|
|
|
.png){kind=logo}
